Literature DB >> 22828962

Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma.

Qinghua Feng1, Huafeng Wei, Janice Morihara, Joshua Stern, Mujun Yu, Nancy Kiviat, Ingegerd Hellstrom, Karl Erik Hellstrom.   

Abstract

OBJECTIVES: To investigate the role of immunological parameters in tumorigenesis of cervical cancer in women infected with high risk human papillomavirus (hr-HPV), and determine whether key findings with human material can be recapitulated in the mouse TC1 carcinoma model which expresses hr-HPV epitopes.
METHODS: Epithelial and lymphoid cells in cervical tissues were analyzed by immunohistochemistry and serum IL10 levels were determined by ELISA. Tumor draining lymph nodes were analyzed in the mouse TC1 model by flow cytometry.
RESULTS: The mucosa was infiltrated by CD20+ and CD138+ cells already at cervical intraepithelial neoplasia 1 (CIN1) and infiltration increased in cervical intraepithelial neoplasia 3 (CIN3)/carcinoma in situ (CIS) and invasive cervical cancer (ICC), where it strongly correlated with infiltration by CD32B+ and FoxP3+ lymphocytes. GATA3+ and T-bet+ lymphoid cells were increased in ICC compared to normal, and expression in epithelial cells of the Th2 inflammation-promoting cytokine TSLP and of IDO1 was higher in CIN3/CIS and ICC. As a corollary, serum levels of IL10 were higher in women with CIN3/CIS or ICC than in normals. Finally we demonstrated in the mouse TC1 carcinoma, which expresses hr-HPV epitopes, an increase of cells expressing B cell or plasma cell markers or Fc receptors in tumor-draining than distal lymph nodes or spleen.
CONCLUSIONS: hr-HPV initiates a local Th2 inflammation at an early stage, involving antibody forming cells, and fosters an immunosuppressive microenvironment that aids tumor progression.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22828962      PMCID: PMC3472044          DOI: 10.1016/j.ygyno.2012.07.098

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  61 in total

Review 1.  Targeting regulatory T cells in cancer.

Authors:  William L Byrne; Kingston H G Mills; James A Lederer; Gerald C O'Sullivan
Journal:  Cancer Res       Date:  2011-11-08       Impact factor: 12.701

Review 2.  Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens.

Authors:  K E Hellström; I Hellström
Journal:  Adv Immunol       Date:  1974       Impact factor: 3.543

3.  Blocking of lymphocyte-mediated cytotoxicity for rat hepatoma cells by tumour-specific antigen-antibody complexes.

Authors:  R W Baldwin; M R Price; R A Robins
Journal:  Nat New Biol       Date:  1972-08-09

4.  Prevalence of genital papillomavirus infection among women attending a college student health clinic or a sexually transmitted disease clinic.

Authors:  N B Kiviat; L A Koutsky; J A Paavonen; D A Galloway; C W Critchlow; A M Beckmann; J K McDougall; M L Peterson; C E Stevens; C M Lipinski
Journal:  J Infect Dis       Date:  1989-02       Impact factor: 5.226

5.  Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents.

Authors:  Anna-Barbara Moscicki; Jonas H Ellenberg; Peggy Crowley-Nowick; Teresa M Darragh; Jiahong Xu; Sepidah Fahrat
Journal:  J Infect Dis       Date:  2004-09-13       Impact factor: 5.226

6.  The immune reaction as a stimulator of tumor growth.

Authors:  R T Prehn
Journal:  Science       Date:  1972-04-14       Impact factor: 47.728

Review 7.  Functional regulation of human neutrophil Fc gamma receptors.

Authors:  Periasamy Selvaraj; Nimita Fifadara; Shanmugam Nagarajan; Ashley Cimino; Guixian Wang
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

8.  Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes.

Authors:  H O Sjögren; I Hellström; S C Bansal; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1971-06       Impact factor: 11.205

9.  Serum-mediated protection of neoplastic cells from inhibition by lymphocytes immune to their tumor-specific antigens.

Authors:  I Hellström; K E Hellström; C A Evans; G H Heppner; G E Pierce; J P Yang
Journal:  Proc Natl Acad Sci U S A       Date:  1969-02       Impact factor: 11.205

10.  Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells.

Authors:  Alexis M Kalergis; Jeffrey V Ravetch
Journal:  J Exp Med       Date:  2002-06-17       Impact factor: 14.307

View more
  42 in total

1.  Association between interluekin-17 gene polymorphisms and the risk of cervical cancer in a Chinese population.

Authors:  Jianglin Cong; Riming Liu; Xuan Wang; Li Sheng; Haiyang Jiang; Weihua Wang; Youzhong Zhang; Shujuan Yang; Chaoying Li
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

2.  The Value of a Novel Panel of Cervical Cancer Biomarkers for Triage of HPV Positive Patients and for Detecting Disease Progression.

Authors:  Norbert Varga; Johanna Mózes; Helen Keegan; Christine White; Lynne Kelly; Loretto Pilkington; Márta Benczik; Schaff Zsuzsanna; Gábor Sobel; Róbert Koiss; Edit Babarczi; Miklos Nyíri; Laura Kovács; Sebe Attila; Borbála Kaltenecker; Adrienn Géresi; Adrienn Kocsis; John O'Leary; Cara M Martin; Csaba Jeney
Journal:  Pathol Oncol Res       Date:  2016-08-06       Impact factor: 3.201

3.  Mediation by peer violence victimization of sexual orientation disparities in cancer-related tobacco, alcohol, and sexual risk behaviors: pooled youth risk behavior surveys.

Authors:  Margaret Rosario; Heather L Corliss; Bethany G Everett; Stephen T Russell; Francisco O Buchting; Michelle A Birkett
Journal:  Am J Public Health       Date:  2014-04-17       Impact factor: 9.308

Review 4.  Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: A review.

Authors:  Javid Sadri Nahand; Mohsen Moghoofei; Arash Salmaninejad; Zahra Bahmanpour; Mohammad Karimzadeh; Mitra Nasiri; Hamid Reza Mirzaei; Mohammad Hossein Pourhanifeh; Farah Bokharaei-Salim; Hamed Mirzaei; Michael R Hamblin
Journal:  Int J Cancer       Date:  2019-10-31       Impact factor: 7.396

5.  Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies.

Authors:  Min Dai; Yuen Yee Yip; Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  Clin Cancer Res       Date:  2014-08-20       Impact factor: 12.531

6.  Correlation between indoleamine 2,3 dioxygenase mRNA and CDKN2A/p16 mRNA: a combined strategy to cervical cancer diagnosis.

Authors:  Mario Cezar Saffi Junior; Ivone da Silva Duarte; Rodrigo Barbosa de Oliveira Brito; Giovana Garcia Prado; Sergio Makabe; Humberto Dellê; Cleber P Camacho
Journal:  Med Oncol       Date:  2016-10-19       Impact factor: 3.064

Review 7.  Immune therapy for human papillomaviruses-related cancers.

Authors:  Ricardo Rosales; Carlos Rosales
Journal:  World J Clin Oncol       Date:  2014-12-10

8.  Ligand-receptor dissociated expression explains high TSLP without prognostic impact in human primary head and neck squamous cell carcinoma.

Authors:  Maude Guillot-Delost; Lia Guilleré; Frédérique Berger; Aurore Ventre; Paula Michea; Philémon Sirven; Lucia Pattarini; Alix Scholer-Dahirel; Fatima-Zahra Kebir; Michel Huerre; Olfa Chouchane-Mlik; Emmanuelle Lappartient; José Rodriguez; Thomas Jouffroy; Jerzy Klijanienko; André Nicolas; Xavier Sastre-Garau; Sofia Honorio; Véronique Mosseri; Nelly Le Peltier; Marie-Paule Sablin; Christophe Le Tourneau; Éric Tartour; Cécile Badoual; Vassili Soumelis
Journal:  Oncoimmunology       Date:  2016-06-07       Impact factor: 8.110

9.  Anti-HE4 antibodies in infertile women and women with ovarian cancer.

Authors:  Ingegerd Hellstrom; Elizabeth Swisher; Karl Erik Hellstrom; Yuen Yee Yip; Kathy Agnew; Judith L Luborsky
Journal:  Gynecol Oncol       Date:  2013-05-28       Impact factor: 5.482

10.  Preclinical evaluation of an innovative anti-TAM approach based on zoledronate-loaded erythrocytes.

Authors:  Raffaella Sabatino; Serafina Battistelli; Mauro Magnani; Luigia Rossi
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.